← All indications
Neuroectodermal Tumors
Malignant neoplasms arising in the neuroectoderm, the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems, including some glial cells.
Subtype terms (4)
More specific conditions that are subtypes of Neuroectodermal Tumors in the MeSH hierarchy.
- Craniopharyngioma
36 drugs (25 approved, 11 experimental)
- Neoplasms, Neuroepithelial
27 drugs (21 approved, 6 experimental)
- Neuroectodermal Tumor, Melanotic
- Neuroendocrine Tumors
225 drugs (95 approved, 130 experimental)
Drugs by status
Phase 3 trials (14)
Phase 2 trials (29)
- mannitol
- ly-3023414
- plerixafor
- antineoplaston AS2-1
- atengenal
- talazoparib
- bvd-523
- irinotecan
- cixutumumab
- pembrolizumab
- palbociclib
- zarnestra
- interleukin-12
- Tasadenoturev
- temozolomide
- bevacizumab
- tazemetostat
- ttrna-dcs
- ttrna-xalt
- zalypsis
- Selpercatinib
- sodium thiosulfate
- erlotinib
- ivosidenib
- melphalan
- iobenguane sulfate i-131
- ensartinib
- ly3023414
- dc/gbm fusion vaccine
Phase 1 trials (27)
Organizations
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (42)
- Daiichi Sankyo
- Amgen
- Imclone
- Merck
- DNAtrix, Inc.
- Jubilant DraxImage Inc.
- NantCell, Inc.
- PharmaMar
- National Institutes of Health (NIH)
- Burzynski Research Institute
- Centre Leon Berard
- Children's Cancer and Leukaemia Group
- University of London
- Cornell University
- Harvard University
- University of Washington
- Herbert Irving Comprehensive Cancer Center
- McGill University
- Newcastle University
- Oregon Health and Science University
- Pediatric Brain Tumor Consortium
- Stanford University
- Thomas Jefferson University
- University of Florida
- University of Leeds
- University of Louisville
- University of Milan
- University of Southern California
- University of Tennessee
- University of Bologna
- +12 more
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (7)